Health Canada approves Pomalyst-based triplet combination for patients with multiple myeloma

Celgene

10 July 2019 - Pomalyst in combination with bortezomib and dexamethasone, provides a new medication option for patients living with multiple myeloma.

Celgene announced today that Health Canada has approved a Pomalyst (pomalidomide)-based triplet combination with bortezomib and dexamethasone. This is a new treatment option for patients with multiple myeloma (MM) who have received at least one prior treatment regimen that included Revlimid (lenalidomide).

Pomalyst is indicated, in combination with bortezomib and dexamethasone, for the treatment of adult patients with MM who have received at least one prior treatment regimen that included lenalidomide.

Health Canada's approval of the Pomalyst-based triplet combination with bortezomib and dexamethasone is based on OPTIMISMM, the first prospective phase 3 trial, including 559 MM patients, to evaluate a Pomalyst-containing triplet regimen in patients.

Read Celgene press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , Canada